Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim AnalysisJordan Gauthier, Filippo Milano, David G. Maloney et al.|Blood|2023Cited by 2
Early prediction of severe ICANS after standard-of-care CD19 CAR T-cell therapy using gradient-boosted classification trees.Jennifer J. Huang, Jordan Gauthier, Emily C. Liang et al.|Journal of Clinical Oncology|2024Cited by 2
139 | ENHANCED CAR T‐CELL EXPANSION AND DURABLE COMPLETE RESPONSES WITH NKTR‐255 PLUS LISOCABTAGENE MARALEUCEL IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMAAlexandre V. Hirayama, Cameron J. Turtle, Jordan Gauthier et al.|Hematological Oncology|2025Cited by 1
Prediction of Therapeutic Potential of CD19 CAR-T Cells for LBCL By Histone Mark Analyses of Core Epigenetic ProgrammingSalvatore Fiorenza, Cameron J. Turtle, Yue Cao et al.|Blood|2024Cited by 1
Phase 2 Study of CD19 CAR T Cells with a Fully Human Binder for Large B-Cell Lymphoma in Relapse or Progression after a Murine Binder-Bearing CD19 CAR T-Cell TherapyJordan Gauthier, Cameron J. Turtle, Jennifer J. Huang et al.|Blood|2023Cited by 0